Compare Medtronic PLC (MDT) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Match Group Inc — how do they compare? Medtronic PLC trades at $88.49 (market cap $112.24B), while Match Group Inc trades at $41.61 (market cap $9.53B). The key difference: Medtronic PLC is far larger — about 11.8× Match Group Inc's market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Match Group Inc for 115 Days on average.
| MDT | MTCH | |
|---|---|---|
Market Cap | $112.24B | $9.53B |
Volume | 105,663,236 | 3,228,794 |
Sector | Health | Media |
52-Week High | $105.35 | $44.40 |
52-Week Low | $73.75 | $28.90 |
Typical Hold Time | 63 Days | 115 Days |
Enterprise Value | $131.58B | $12.49B |
Dividend Yield | 3.28% | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $87.80, up 2.68% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 13.93% net income margin and consistent dividend growth over 49 years. Revenue growth accelerated to $33.54B in 2025, and analyst consensus targets $97.80, implying 11% upside. Recent news highlights regulatory approvals for medical devices and a $4B MiniMed exchange offer.
MDT offers value with a 3.2% dividend yield and reasonable valuation (P/E 21.6), but faces headwinds from technical bearishness and rising debt. The stock's appeal hinges on execution of growth initiatives in cardiovascular and neuroscience segments, though competitive and macroeconomic risks persist.
MTCH trades at $41.48, up 1.52% today, near the consensus price target of $42.29. The stock shows a bullish technical trend with strong moving averages, though RSI indicates potential overbought conditions. Fundamentally, the company maintains robust profitability with a 20.17% net income margin and positive cash flow trends, while recent earnings have been mixed with a beat in Q2 2026 but a miss in Q1 2026. Positive sentiment is driven by product innovation at Tinder and growth from Hinge.
The outlook for MTCH is positive, supported by analyst consensus leaning buy (53% of ratings) and a projected EPS beat in Q3 2026. Investment opportunities include margin expansion and AI-driven product enhancements, but risks involve high debt levels and competitive pressures in the dating app market. Shareholder value may benefit from sustained cash flow generation and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
